MONTREAL, QC / ACCESSWIRE / July 1, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce, that effective June 30th, 2020, it has signed a letter of intent to pursue a Partnership where Jugular will support and offer its expertise to the Company in creating a specialized division within MJ Medtech that focuses on marketable innovation within the functional foods sector.
Functional Food is defined as any modified food that claims to improve health or well-being by providing benefits beyond that of the traditional nutrients it contains.
It is anticipated that the letter of intent will be replaced with a formal agreement governing the Partnership on or before September 30, 2020. The Parties will define their collaboration for the development and manufacturing of CBD Functional Foods immediately under the Dr. AnnaRx brand:
Immune Booster Shot: The pandemic has caused a significantly heightened awareness for immune-boosting supplements that are easily ingested. Special African medicinal roots and herbs are used in combination to create this very powerful immune booster tonic.
Energy Booster Shot: Quick energy on the go. The ultimate coffee powered CBD infused shot to get added energy into your system and amplify mental clarity quickly and effectively.
Relax and Unwind Shot: This powerful formulation of Rooibos, CBD, and 8 other African medicinal herbs will help relieve many of the tensions built up during the day enabling you to enjoy a most peaceful sleep.
"Jack and I have spent immeasurable hours over the past few years discussing food science and how we might see a fit in bringing the brains behind our organizations together. We are thrilled to make this a reality and to be working with a group that cares as much about the science as we do" said Jeff Robinson, Chief Executive Officer of Wuhan General Group.
Jack Napier, Jugular Director added: "Jeff and his team at M2BIO are putting everything in place to create the right moment to bring cannabinoid-based nutraceuticals to the mass market. Jugular in partnership with M2BIO will use its extensive experience in the functional foods retail sector to unlock a new area of global profitability in the fast-growing wellness industry. We are thrilled to begin this partnership as we see the enormous potential of creating marketable innovations in this untapped new field within functional nutrition."
About Jugular
Jugular is an innovation partner within the wellness sector, implementing our skills to bring new functional food & nutraceutical products from concept to market. Jugular comprises a cross-specialized team of wellness professionals and scientists that are passionate about making a positive impact on the world by advocating a healthy lifestyle through innovative products that are good for you. We own multiple functional food brands that are sold throughout Europe and distributed Internationally.
​​Our Vision
​We seek to develop groundbreaking products incorporating new & novel ingredients into the wellness sector.
​Our Mission
​To help as many people as possible get access to advanced nutritional products. To educate, inform and break down the stigma surrounding novel foods.
​Our Strategy
​Jugular brings cutting edge new products from the concept phase through the critical path to launch. We provide expertise in sourcing, designing, manufacturing, logistics & marketing over a broad array of products including:
- Functional Foods & RTE (Ready to Eat)
- Ready to Drink shots and bottles
- Powder supplements
- Capsules, softgel and hard form nutraceuticals
We help producers and innovators of new novel ingredients find their way to the mainstream & the profitability that comes with it. Our team will guide our partners along the often-tricky path to project completion in good time.
We take fresh ideas and put them into as many hands as possible. Using market trends analysis, we determine when and how to strike with the new products that take the world by storm.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer's and Parkinson's. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".
For further information:
Publicly traded company (OTC Pink:WUHN)
Website: www.wuhn.org
E-mail:[email protected]
Follow us on Twitter: https://twitter.com/WGG_Company
Follow us on Facebook: http://www.facebook.com/wuhn
Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc.